A Phase 2 interventional study of 50 mg Cannabidiol (CBD) and Placebo in Sleep Disturbance, Insomnia and Insomnia Type; Sleep Disorder, sponsored by Bod Australia. Completed at 2 sites in Australia. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-08-16.
Sponsored by Bod Australia · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies in Sleep Initiation and Maintenance Disorders with a site in Australia — 9 open to participants now, 10 under way, 1 of them phase 3. Sleep Initiation and Maintenance Disorders · Australia.
Among the 25 studies in Sleep Initiation and Maintenance Disorders with a site in Australia, this one is the 14th largest by enrollment, is one of 3 that started in 2022, is one of 4 in phase 2, and was the 12th registered.
2,729 studies on the registry are indexed under Sleep Initiation and Maintenance Disorders; 731 are open to participants now.
Browse Sleep Initiation and Maintenance Disorders studies →9 of the 25 studies in Sleep Initiation and Maintenance Disorders with a site in Australia are open now. Recruiting first, the newest first:
Woolcock Institute of Medical Research · Sites in Australia
Ages 30–65
Woolcock Institute of Medical Research · Sites in Australia
Ages 16–24
University of Sydney · Sites in Australia, United States
Ages 18+
Woolcock Institute of Medical Research · Sites in Australia
Ages 18–45
Woolcock Institute of Medical Research · Sites in Australia
Ages 55+
A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →
Of the 390 Sleep Initiation and Maintenance Disorders studies recruiting now, 153 (39%) set no upper age limit and 207 (53%) stop at 75 or younger; 59 take children under 18; 109 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 5 · Phase 3 10 · Phase 4 1
First in 2003; this study’s year is marked. 3 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 208 is above the median of 68 across 2,356 interventional studies indexed under Sleep Initiation and Maintenance Disorders.
Median enrollment 270 across the 25 interventional studies. Of the 15 that completed or were terminated, 2 (13%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 25 have an industry lead sponsor. The 10 most frequent:
Bod Australia is the lead sponsor of 2 studies on the registry; none are open to participants now.
Bod Australia has 1 study filed under Sleep Initiation and Maintenance Disorders — fewer than ten, so there is no comparison to draw.
4 of the studies in Sleep Initiation and Maintenance Disorders with a site in Australia that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05840822Phase 3Avecho BiotechnologyEvaluating Efficacy and Safety of CBD TPM Capsules for Use in Insomnia | 2027-09-30 |
| NCT06114901Woolcock Institute of Medical ResearchEfficacy of Mobile-delivered Sleep Restriction Therapy for Treatment of Insomnia Disorder: Randomised Controlled Trial | 2026-12-01 |
| NCT07392177Woolcock Institute of Medical ResearchUnderstanding the Role of the Locus Coeruleus in Insomnia | 2027-03 |
| NCT07405775Woolcock Institute of Medical ResearchSleepFix for Youth: Digital Behavioural Therapy for Insomnia With E-Psychologist Support | 2027-11-01 |
Add all 4 to your calendar (.ics) → With an account.
Among the 25 studies in Sleep Initiation and Maintenance Disorders with a site in Australia, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study aims to investigate the effect of 50 mg and 100 mg per day oral CBD product versus a placebo over 8 weeks on insomnia severity in adults aged 18-65 years old with insomnia symptoms.
This is a double-blind, randomised, parallel-group, placebo-controlled study of 8 weeks of oral CBD at 50 or 100 mg per day versus placebo in 198 participants with insomnia symptoms as classified by an Insomnia Severity Index (ISI) score of 8-21. Participants will be recruited voluntarily and are able to withdraw at any time. The study will be conducted online with telehealth consults where required.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The use of any drug known to affect sleep during the study one week prior the randomization, including:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
50 mg CBD to be administered as a single oral dose. Each capsule contains 25 mg CBD. Two capsules to be taken (plus two placebo capsules)
Drug: 50 mg Cannabidiol (CBD) · Drug: Placebo · Drug: 100 mg Cannabidiol (CBD)
100 mg CBD to be administered as a single oral dose. Each capsule contains 25 mg CBD. Four capsules to be taken.
Drug: 50 mg Cannabidiol (CBD) · Drug: 100 mg Cannabidiol (CBD)
Placebo capsules contain no CBD. Four capsules to be taken as a single oral dose.
Drug: Placebo
For the study arm, '50 mg CBD' participants take two (2) CBD capsules and two (2) placebo capsules.
Also known as: BodECS BioAbsorb(TM) capsule
Participants take four (4) placebo capsules.
For the study arm, '100 mg CBD' participants take four (4) CBD capsules.
Also known as: BodECS BioAbsorb(TM) capsule
To investigate the effect of the administration of a 50mg and 100mg per day oral CBD product versus placebo over 8 weeks on insomnia severity index scores
Insomnia Severity Index (ISI): A 7-item tool measuring the nature, severity, and impact of insomnia over the past 2 weeks. Each item uses a 5-point Likert scale to capture a rating (0 = no problem; 4 = very severe problem) which add up to: no insomnia (0 - 7); sub-threshold insomnia (8 - 14); moderate insomnia (15 - 21); and severe insomnia (22 - 28).
Time frame: Baseline (week 0), week 4, week 8
To determine the effect of 8 weeks of 50mg or 100mg of CBD compared to placebo on wake after sleep onset (WASO) as assessed by actigraphy.
WASO is a parameter that examines the total amount of minutes awake after the first sleep epoch is achieved. Therefore, as the WASO increases, sleep efficiency decreases.
Time frame: Baseline (week 0), week 8
To determine the effect of 8 weeks of 50mg or 100mg of CBD compared to placebo on Anxiety as assessed by the DASS-21 questionnaire.
Depression Anxiety Stress Scale-21 (DASS-21): A 21-item tool with subscales measuring the negative emotional states of depression, anxiety, and stress separately. Depression ranges from normal (0-9) to extremely severe (28+); anxiety ranges from normal (0-7) to extremely severe (20+); and stress ranges from normal (0-14) to extremely severe (34+).
Time frame: Baseline (week 0), Week 4, week 8
To determine the effect of 8 weeks of 50mg or 100mg of CBD compared to placebo on Stress as assessed by the DASS-21 questionnaire.
Depression Anxiety Stress Scale-21 (DASS-21): A 21-item tool with subscales measuring the negative emotional states of depression, anxiety, and stress separately. Depression ranges from normal (0-9) to extremely severe (28+); anxiety ranges from normal (0-7) to extremely severe (20+); and stress ranges from normal (0-14) to extremely severe (34+).
Time frame: Baseline (week 0), Week 4, week 8
To determine the effect of 8 weeks of 50mg or 100mg of CBD compared to placebo on Sleep onset latency (SOL) measured by actigraphy.
Sleep onset latency (SOL) is the time it takes to transition from wakefulness to non-REM sleep. On average, the SOL should take between 10-20 minutes. Short sleep latencies usually reflect increased sleepiness.
Time frame: Baseline (week 0), week 8
To determine the effect of 8 weeks of 50mg or 100mg of CBD compared to placebo on subjective sleep as assessed by sleep diaries
Participants will be requested to complete a short, 5-minute online sleep diary for seven mornings to describe the previous night's sleep at baseline, week 4 and week 8.
Time frame: Baseline (week 0), week 4, week 8
To determine the effect of 8 weeks of 50mg or 100mg of CBD compared to placebo on self-perception of improvement in sleep as assessed by a self-report questionnaire.
The self-report questionnaire will ask participants to rate their self-perceived improvement in sleep using a standard 10-point visual analogue scale at weeks 4 and 8
Time frame: Baseline (week 0), week 4, week 8
To determine the effect of 8 weeks of 50mg or 100mg of CBD compared to placebo on Subjective sleep-related quality of life as assessed by the Functional Outcomes Sleep Questionnaire (FOSQ-10).
FOSQ-10 is a 10 items questionnaire to measure the impact of daytime sleepiness on activities of daily living. The score range is 5-20 points, with higher scores indicating better functional status.
Time frame: Baseline (week 0), week 4, week 8
To determine the effect of 8 weeks of 50mg or 100mg of CBD compared to placebo on Fatigue assessed by the Flinders Fatigue Scale;
The Flinders Fatigue Scale is a 7 items self-report scale which assess fatigue over the past 2 weeks. This scale provides a total fatigue score ranging from 0 to 31, with higher scores indicating greater fatigue.
Time frame: Baseline (week 0), week 4, week 8
To determine the effect of 8 weeks of 50mg or 100mg of CBD compared to placebo on Health-related quality of life (HRQoL) assessed using the EQ-5D-5L.
A descriptive system for health-related quality of life states in adults, consisting of five dimensions. Each of which has five severity levels that are described by statements appropriate to that dimension. Those are rated by a verbal 5-point rating scale allowing for distinction of five levels ('5L') of severity: Level 1: no problems; Level 2: slight problems; Level 3: moderate problems; Level 4: severe problems; Level 5: extreme problems per dimension and providing a 1-digit number for each dimension.
Time frame: Baseline (week 0), week 4, week 8
To determine the effect of 8 weeks of 50mg or 100mg of CBD on the number of participants with treatment-emergent adverse events
The safety and tolerability of the investigational product will be determined by evaluating all incidences of treatment-emergent adverse events as assessed by reported by participants or observed by the investigators or from the safety pathology tests.
Time frame: Week 4, Week 8, Week 12
To determine relationship between efficacy endpoint and systemic concentrations of CBD and its carboxy and hydroxy metabolites
Systemic concentrations of CBD (ng/mL), 7- hydroxycannabidiol (7-OH-CBD) (ng/mL) and 7- carboxycannabidiol (7- COOH-CBD) (ng/mL) will be analysed in plasma and urine samples collected at baseline and week 8.
Time frame: Baseline (week 0), week 8
To determine the effect of 8 weeks of 50mg or 100mg of CBD compared to placebo on Depression as assessed by the DASS-21 questionnaire.
Depression Anxiety Stress Scale-21 (DASS-21): A 21-item tool with subscales measuring the negative emotional states of depression, anxiety, and stress separately. Depression ranges from normal (0-9) to extremely severe (28+); anxiety ranges from normal (0-7) to extremely severe (20+); and stress ranges from normal (0-14) to extremely severe (34+).
Time frame: Baseline (week 0), Week 4, week 8
Plan to share: No
No publications or documents are linked to this record.
Ran from May 2022 to primary completion in Jul 2023, 14 months.
Of 27 industry-sponsored phase 2 interventional studies under Sleep Initiation and Maintenance Disorders, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 16. This study's 14 months is close to that.
Counting every sponsor, half of 63 studies reached it within 17 months; a quarter within 12 and three quarters within 40.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cannabidiol
Sleep Initiation and Maintenance Disorders →
Bod Australia